Keywords: GlaxoSmithKline, USA, Tykerb, Lamictal, Approval, Breast cancer, Epilepsy, Employment,

US FDA clears new uses for two GlaxoSmithKline drugs; Tykerb and Lamictal; GSK set to announce 3,000 job cuts

Article | 1 February 2010

UK drug giant GlaxoSmithKline received two pieces of good news from the US Food and Drug Administration last Friday related to its breast cancer drug Tykerb (lapatinib) and Lamictal XR (lamotrigine), currently indicated for epilepsy and for maintenance treatment of bipolar I disorder.

On January 29, the FDA has granted accelerated approval for a new combination regimen using Tykerb as a first-line, all-oral treatment for women with metastatic breast cancer. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in